Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Diversifies In China With $70 Million To Expand Production Capability For Animal Health Division Merial

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Sanofi-Aventis' animal health division Merial Animal Health broke ground on a $70 million expansion of its Nanchang manufacturing site, six months after Sanofi CEO Chris Viehbacher said his company aims to diversify in China

You may also be interested in...



Where’s The Beef? China Pushes For More Stringent Controls On Veterinary Drugs

A draft proposal by the Ministry of Agriculture comes at a time when several Big Pharma are pursuing opportunities in China’s veterinary market.

Pfizer, Sanofi-Aventis, Eli Lilly: Emerging Markets Earnings Roundup (Part 3 of 3)

A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1, and Pfizer as the first American pharma to break out emerging market sales by product. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.

Pfizer, Sanofi-Aventis, Eli Lilly: Emerging Markets Earnings Roundup (Part 3 of 3)

A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1, and Pfizer as the first American pharma to break out emerging market sales by product. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel